Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023 02:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44th...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
June 01, 2023 15:40 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 1, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
May 31, 2023 08:15 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 31, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
May 25, 2023 17:10 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphomaPoster presentations...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
May 23, 2023 15:14 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 23, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,098 shares as a consequence of the exercise of employee warrants. The...
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
May 19, 2023 12:33 ET
|
Genmab A/S
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median...
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023 11:01 ET
|
Genmab A/S
May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In...
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
April 24, 2023 04:39 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second...
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
April 20, 2023 19:45 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc....
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
April 18, 2023 06:25 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...